Medication appears helpful for treatment of erectile dysfunction in men with spinal cord injuriesSeptember 11, 2007The drug tadalafil appears to improve erectile function in men with spinal cord injuries, according to an article posted online today that will appear in the November 2007 print issue of Archives of Neurology, one of the JAMA/Archives journals. Between 10.4 and 83 individuals per million worldwide experience spinal cord injuries every year, according to background information in the article. "Throughout the world, spinal cord injury occurs most often in young men, resulting in negative physical, social and psychological consequences," the authors write. "Erectile dysfunction, defined as the inability to attain and maintain penile erection sufficient for satisfactory sexual performance, is a common complication in men with spinal cord injury." Only 25 percent of men with spinal cord injuries are able to have erections that are adequate for having intercourse. Francois Giuliano, M.D., Ph.D., of the Raymond Poincare Hospital, Garches, France, and colleagues, conducted a randomized, double-blind study of tadalafil in 197 men with spinal cord injuries (average age 38). After a four-week period during which none of the men received treatment, 142 were randomly assigned to the tadalafil treatment group and 44 to the placebo group. During the 12-week treatment phase, the participants were instructed to take the medication as needed before the potential for sexual activity, with a maximum of one dose daily. Those assigned to take tadalafil were given a 10-milligram dose at first and were evaluated every four weeks, at which time patients were switched to a 20-milligram dose based on their response to the treatment.
At the beginning of the study, the men's average score on the International Index of Erectile Function-a 15-item questionnaire on which a score of 25 or lower indicates erectile dysfunction-was 13.4. After 12 weeks of treatment, men taking tadalafil had an average score of 22.6 (indicating mild erectile dysfunction) and men taking placebo had an average score of 13.6 (indicating moderate erectile dysfunction). Men taking tadalafil were, on average, successful 75.4 percent of the times they attempted penetration and 47.6 percent of the times they attempted intercourse, compared with a 41.1 success rate for penetration and 16.8 percent for intercourse among men taking placebo. "Tadalafil was safe and well tolerated with few treatment-emergent side effects," the authors write. Fifty (35 percent) of patients in the tadalafil group and 15 (34 percent) of those in the placebo group experienced at least one adverse effect. Among those taking tadalafil, the most common side effects were headache (8.5 percent of patients) and urinary tract infection (7.7 percent of patients). "As in other erectile dysfunction studies that include patients who were difficult to treat owing to pre-existing conditions (e.g., prostatectomy, diabetes mellitus), tadalafil was efficacious for the treatment of erectile dysfunction after a traumatic spinal cord injury," the authors write. "On-demand treatment with tadalafil (10 milligrams or 20 milligrams) may help improve the sex lives of patients with erectile dysfunction and spinal cord injury and their partners." JAMA and Archives Journals | |||||||||||||||||||||
|
Related Spinal Cord News Articles Alcohol consumption can cause too much cell death, fetal abnormalities The initial signs of fetal alcohol syndrome are slight but classic: facial malformations such as a flat and high upper lip, small eye openings and a short nose. New hope for stroke patients If a stroke patient doesn't get treatment within approximately the first three hours of symptoms, there's not much doctors can do to limit damage to the brain. Teens underestimate risk, overestimate vehicle, highway safety in motor vehicle accidents Most teens' attitudes regarding trauma-related injuries, particularly those due to motor vehicle crashes, reflect an sense of invincibility and focus on fate rather than choice, according to new research published in the August issue of the Journal of the American College of Surgeons. Multiple Sclerosis: new MRI contrast medium enables early diagnosis in animal model In an animal model of multiple sclerosis (MS), neuroradiologists and neurologists of the University hospitals of Heidelberg and Würzburg have been able to visualize inflammatory tissue damage, most of which had remained unrecognized up to now, with the aid of a new contrast medium, Gadofluorine M, in magnetic resonance imaging. Protein plays Jekyll and Hyde role in Lou Gehrig's disease Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease, is a fatal neurodegenerative disease caused by the death of motor neurons in the brain and spinal cord that control muscle movements from walking and swallowing to breathing. In a groundbreaking study this week in PLoS Biology, Brandeis and Harvard Medical School scientists report key findings about the cause and occurrence of the familial form of ALS. Adult stem cells activated in mammalian brain Adult stem cells originate in a different part of the brain than is commonly believed, and with proper stimulation they can produce new brain cells to replace those lost to disease or injury, a study by UC Irvine scientists has shown. MIT identifies cells for spinal-cord repair A researcher at MIT's Picower Institute for Learning and Memory has pinpointed stem cells within the spinal cord that, if persuaded to differentiate into more healing cells and fewer scarring cells following an injury, may lead to a new, non-surgical treatment for debilitating spinal-cord injuries. Stanford researchers take first look at working muscle fiber Using an unusual microscope with a tip the size of a needle, Stanford researchers are now able to look at tiny fibers of working muscles in live humans, with minimum discomfort to the patient-a development patients are sure to welcome. Pitt-led Research Provides Insight Into Development of Common Congenital Circulatory Defects University of Pittsburgh-led researchers could provide new insight into how two common congenital circulatory problems-aortic arch deformity and arteriovenous malformations (AVMs)-develop in humans, as reported in the June 15 edition of Developmental Biology. Best treatment for MS may depend on disease subtype Animal studies by University of Michigan scientists suggest that people who experience the same clinical signs of multiple sclerosis (MS) may have different forms of the disease that require different kinds of treatment. More Spinal Cord News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||